First Complete Response in Concurrent BTKi azer-cel Cohort
Filed with ASX · · 3 pages · English
Story so far
Earlier from Imugene
- Azer-cel Granted FDA Fast Track Designation for CLL and MZL
- First Patient in BTKi Combination Cohort of azer-cel study
- Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
- Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)
- Prospectus
Later from Imugene
- New Complete Response in the Concurrent BTKi azer-cel Cohort
- $11.1 Million Placement Completed to Advance azer-cel
- Third response in concurrent BTKi Cohort of azer-cel Trial
- azer-cel BTKi Cohort Reports new Complete & Partial Response
- Further Responses in azer-cel Phase 1b Trial
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene